Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

11.28
+0.37003.39%
Pre-market: 11.10-0.1800-1.60%07:32 EDT
Volume:901.30K
Turnover:9.95M
Market Cap:218.17M
PE:-1.85
High:11.37
Open:10.81
Low:10.58
Close:10.91
52wk High:20.56
52wk Low:7.12
Shares:19.34M
Float Shares:17.42M
Volume Ratio:1.47
T/O Rate:5.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:2.13
PE(LYR):-1.91

Loading ...

MercadoLibre, T-Mobile, Corbus, Celestica, Elevance Trending With Analysts

TIPRANKS
·
May 02

Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.3%, Outperforms Peers

Dow Jones
·
May 02

Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.22 a share - Earnings Preview

Reuters
·
May 01

Corbus Pharmaceuticals Initiated at Buy by Guggenheim

Dow Jones
·
Apr 30

U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings

Reuters
·
Apr 29

Corbus Pharmaceuticals Holdings Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $45

THOMSON REUTERS
·
Apr 29

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Apr 29

Corbus Pharmaceuticals initiated with a Buy at Guggenheim

TIPRANKS
·
Apr 29

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Apr 25

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 23

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

GlobeNewswire
·
Apr 22

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Apr 22

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 17

Corbus Pharmaceuticals Updates Executive Employment Agreements and Protections

TIPRANKS
·
Apr 17

Corbus CEO Cohen base salary rises to $673,625 under amended employment agreement

Reuters
·
Apr 17

Corbus Pharmaceuticals announces last person enrolled in CANYON-1 trial

TIPRANKS
·
Apr 14

Corbus enrolls last patient in Phase 1b CANYON-1 obesity trial of CRB-913

Reuters
·
Apr 14

Corbus Pharmaceuticals Holdings Inc - Canyon-1 Study on Track for Completion in Summer 2026

THOMSON REUTERS
·
Apr 14

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 14

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 10